Cellectar Biosciences
CLRB
6 hedge funds and large institutions have $6.88M invested in Cellectar Biosciences in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50.32% more ownership
Funds ownership: 0% → 50.32% (+50%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
+$6.39M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.07M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.55M |
| 4 |
Sophrosyne Capital
New York
|
+$518K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$259K |
Top Sellers
CLRB Hedge Fund Activity: Q3 2014 in Review
6 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2014, worth a combined $6.88M.
Buyers outnumbered sellers: 6 funds opened new CLRB positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Austin W. Marxe & David M. Greenhouse, opening a new position worth an estimated $6.39M.
- 6 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $6.88M of Cellectar Biosciences stock for Q3 2014.
- 6 funds opened new Cellectar Biosciences positions in Q3 2014 and 0 closed out, a net change of +6 holders.
- The largest Cellectar Biosciences buyer in Q3 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $6.39M added.
Based on aggregated 13F filings for Q3 2014.